Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

被引：28

作者：

De Stefano, Nicola ^{[1
]}

Curtin, Francois ^{[2
,7
]}

Stubinski, Bettina ^{[2
,7
]}

Blevins, Gregg ^{[3
]}

Drulovic, Jelena ^{[4
]}

Issard, Delphine ^{[2
,7
]}

Shotekov, Penko ^{[5
]}

Gasperini, Claudio ^{[6
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy

[2] Merck Serono SA, Geneva, Switzerland

[3] Univ Alberta, Div Neurol, Edmonton, AB, Canada

[4] Univ Belgrade, Inst Neurol, Clin Ctr Serbia, Belgrade, Serbia

[5] UMBAL Alexandovska, Neurol Clin, Sofia, Bulgaria

[6] San Camillo Forlanini Hosp, Rome, Italy

[7] Merck KGaA, Darmstadt, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2010年 / 16卷 / 07期

关键词：

efficacy; interferon beta-1a; magnetic resonance imaging; randomized controlled trial; relapsing-remitting multiple sclerosis;

D O I：

10.1177/1352458510362442

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

w This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta 1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n=180) were randomized (2:1) to IFN-beta 1a or placebo for 16 weeks; all patients then received IFN-beta 1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta 1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-beta 1a by week 4 ( post hoc analysis; p=0.015). The new formulation of sc IFN-beta 1a has rapid beneficial effects on MRI outcomes in RRMS.

引用

页码：888 / 892

页数：5

共 50 条

[1] Interferon beta-1a in relapsing-remitting multiple sclerosis
Blumhardt, L
[J]. HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
[2] Interferon beta-1a in relapsing-remitting multiple sclerosis: A meta-analysis
Blumhardt, LD
[J]. NEUROLOGY, 1999, 52 (06) : A498 - A498
[3] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
Vazquez Gomez, Lazaro Aurelio
Hidalgo Mesa, Carlos
Broche Perez, Yunier
Valdes Morales, Yanet
[J]. MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
[4] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
Munschauer, FE
Stuart, WH
[J]. CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
[5] Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis
Rudick, R.
Pace, A.
Panzara, M.
Rani, S.
Schrock, J.
Calabresi, F.
Confavreux, C.
Galetta, S.
Lublin, F.
Radue, E. W.
Stuart, W.
Weinstock-Guttman, B.
Wynn, D.
[J]. MULTIPLE SCLEROSIS, 2007, 13 : S57 - S57
[6] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
Gitlin, M.
Snyder, S.
Jhaveri, M.
[J]. VALUE IN HEALTH, 2019, 22 : S746 - S746
[7] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Gitlin, M.
Snyder, S.
Jhaveri, M.
[J]. VALUE IN HEALTH, 2019, 22 : S744 - S744
[8] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Espallardo, O.
Crespo, C.
Polanco, C.
Nieves, D.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
[9] Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
De Stefano, Nicola
Sormani, Maria Pia
Stubinski, Bettina
Blevins, Gregg
Drulovic, Jelena S.
Issard, Delphine
Shotekov, Penko
Gasperini, Claudio
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 97 - 101
[10] Effect of interferon beta-1a on grey matter atrophy progression in relapsing-remitting multiple sclerosis
Zivadinov, R
Locatelli, L
Srinivasaraghavan, B
Ukmar, M
Bratina, A
Maggiore, C
Bosco, A
Grop, A
Pozzi-Mucelli, R
Catalan, M
Zorzon, M
[J]. MULTIPLE SCLEROSIS, 2005, 11 (01): : 115 - 115

← 1 2 3 4 5 →